Skip to main content

Maria Mar Hernandez Guillamon

Senior Researcher, Neurovascular Research Lab, VHIR.

Institutions of which they are part

Main researcher
Neurovascular Diseases
Vall Hebron Institut de Recerca

Maria Mar Hernandez Guillamon

Institutions of which they are part

Main researcher
Neurovascular Diseases
Vall Hebron Institut de Recerca

Senior Researcher, Neurovascular Research Lab, VHIR.

Dr. Mar Hernández-Guillamon has dedicated her career to the study of cerebral amyloid angiopathy (CAA) and other pathologies associated with the deposition of amyloid-beta (Abeta). In 2013, she was awarded by Carlos III Spanish Health Institute with the Miguel Servet contract to establish the Cerebral Amyloidosis line of research at VHIR. Her group has positioned in forefront of the Abeta-pathologies field, studying the molecular mechanisms involved in the Abeta transport and metabolism using in vitro and in vivo models. Her lab has also dedicated to the clinical research and discovery of biomarkers associated with CAA and other cerebrovascular diseases. The translational research developed by Dr. Hernandez-Guillamon's group has allowed the achievement of important aims to date, as demonstrated by the scientific production obtained (h-index= 35, 80 publications, >3700 citations) and the continuous leadership of national and international projects.

Projects

INVICTUS

IP: Joan Montaner Villalonga
Collaborators: Marta Aurora Rubiera Del Fueyo, Jorge Pagola Pérez Blanca, INVICTUS, José Alvarez Sabin, Anna Penalba Morenilla, Maria Mar Hernandez Guillamon, INVICTUS, Marc Ribó Jacobi, Maria Pilar Delgado Martínez, Carlos Molina Cateriano, Anna Rosell Novel, David Rodriguez Luna, Mª Ángeles Muchada López, Estevo Santamarina Pérez
Funding agency: Instituto de Salud Carlos III
Funding: 247695.66
Reference: RD12/0014/0005
Duration: 01/01/2013 - 31/03/2017

Role of Apolipoproteins (ApoE, ApoJ and ApoA-1) in Cerebral Amyloid Angiopathy: study of â-amyloid traffic across the blood brain barrier

IP: Maria Mar Hernandez Guillamon
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 119290
Reference: CP12/03259
Duration: 01/01/2013 - 31/01/2016

Role of Apolipoproteins (ApoE, ApoJ and ApoA-1) in Cerebral Amyloid Angiopathy: study of â-amyloid traffic across the blood brain barrier

IP: Joan Montaner Villalonga
Collaborators: Maria Mar Hernandez Guillamon, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 202500
Reference: MS12/03259
Duration: 01/01/2013 - 31/12/2017

Estada al Dpt. de Patologia del New York University Medical School

IP: Joan Montaner Villalonga
Collaborators: Maria Mar Hernandez Guillamon
Funding agency: Instituto de Salud Carlos III
Funding: 1800
Reference: ESTSB-2010-01
Duration: 11/05/2010 - 14/07/2010

Related news

The TOUCH MSCA-COFUND doctoral training programme, led by UAB and focusing on the field of mental health, has opened its first call for applications, offering 13 doctoral positions.

The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.

La recerca és fonamental per contrarestar els efectes de la pol·lució, que segons l’AEMPS, va ser la causa de més de 300.000 morts prematures a la UE el 2020.

Related professionals

Carlos Molina Cateriano

Carlos Molina Cateriano

Head of group
Stroke research
Read more
Arnau Peñalver Piñol

Arnau Peñalver Piñol

Predoctoral researcher
Epidemiology and Public Health
Read more
Toni Soriano Colomé

Toni Soriano Colomé

Research technician
Cardiovascular Diseases
Read more
Pablo Gabriel Medina

Pablo Gabriel Medina

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.